ProBio Inc., a contract development and manufacturing organization, on Tuesday announced the expansion of its plasmid DNA and viral vector manufacturing capabilities with the opening of a new state-of-the-art facility in Hopewell. The facility will serve as the hub for North American operations, significantly enhancing ProBio’s capability to support the manufacturing of life-changing cell and gene therapies in North America.
Spanning approximately 128,000 square feet, the Hopewell facility encompasses office, laboratory and manufacturing spaces outfitted with the latest equipment and technology for process development and current good manufacturing practice production of plasmid DNA and viral vectors, including adeno-associated virus, lentivirus and retrovirus.
This site supports tech transfer, method and analytical development, process development, drug substance, drug product manufacturing for both clinical and commercial-grade plasmid DNA and viral vector-based therapies. All operations are maintained with rigorous quality control and quality assurance processes.
“We are proud to expand our capabilities to manufacture life-changing biologic drugs to the growing cell and gene therapy industry. Our dedicated, talented team and state-of-the-art manufacturing facility here in Hopewell will help expedite bringing these therapies to patients,” Li Chen, CEO of ProBio, said. “This expansion underscores our commitment to accelerating the delivery of advanced therapies to patients.”
The facility’s cGMP suites will undergo renovation to produce plasmid DNA and viral vectors for phase-appropriate programs, enhancing the company’s capabilities and reinforcing its leading position in the biotech sector.
